Drugs / Alfosbuvir
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT04070235 | Mar → Dec 2019 | chronic hepatitis C virus infection | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Unknown | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alfosbuvir | “Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection.” PMID 37856013 ↗ Oct 2023 |
| Action | Inhibit | “Alfosbuvir is a novel potent HCV NS5B polymerase inhibitor in development for the treatment of chronic HCV infection.” PMID 37856013 ↗ Oct 2023 |
| Route | Oral | “Once-daily oral administration of alfosbuvir plus daclatasvir were highly effective and safe in Chinese patients infected with HCV genotype 1, 2, 3 or 6” PMID 35080256 ↗ Apr 2022 |